AMERICAN ACADEMY OF DERMATOLOGY SKIN DISEASE BRIEFS



Skin infections by the numbers

Skin infections are among 24 skin diseases or disease categories examined in the Burden of Skin Disease report commissioned by the American Academy of Dermatology. The report examined prevalence, economic burdens, and mortality for skin disease in the U.S. using 2013 health care claims data drawn from insurance enrollment and claims databases and found that:

- **84.5 million** Americans one in four saw a physician for skin disease; 50% of them are over 65 and have an average of 2.2 skin conditions.
- Skin disease cost the U.S. healthcare system \$75 billion in medical, preventative, and prescription and non-prescription drug costs.
- One in three Americans with skin disease were seen by a dermatologist, who collaborate with other physicians throughout the health care system in caring for these patients.


When combined, over 40.8 million individuals sought medical treatment for skin infections in 2013, which is almost 1 in 2 Americans affected by skin disease. The three disease areas — viral and fungal diseases, cutaneous infections, and HPV (human papillomavirus/molluscum) — were each among the top 5 by number of affected people that sought care in 2013. That year:

- The medical cost of treating skin infections exceeded \$11.4 billion and each of the three disease areas were among the top 5 by cost, with cutaneous infections at the top totaling \$8.1 billion.
- The combined <u>lost productivity costs for individuals and caregivers affected was over \$3.3</u> <u>billion</u>, almost one third of the total lost productivity for the 24 skin disease categories analyzed.
- Nearly 2,500 people died of cutaneous infections and viral and fungal diseases.


The charts that follow provide topline data on how skin infections contribute the overall burden of skin disease.

The full report includes data on prescription and non-prescription drug costs, and how age and insurance status and provider relate to the burden associated with skin infections and skin disease broadly. To purchase the report visit www.aad.org/BSD.

Prevalance




^{*}This category is clinically broad in nature and includes, among other diseases: benign neoplasms, melanocytic nevi (unspecified), pilar cysts, pilonidal cysts (with or without abscess), scars and fibrosis, etc.



^{*}Percentage of skin ulcer, wound, and burn patients seen by a physician by age group.


Cost



^{*}In millions of dollars compared to most costly skin diseases.

^{***} Represents combined data for melanoma and nonmelanoma skin cancer.






^{*}Compared with most costly skin diseases.


^{**}This category is clinically broad in nature and includes, among other diseases: benign neoplasms, melanocytic nevi (unspecified), pilar cysts, pilonidal cysts (with or without abscess), scars and fibrosis, etc.

^{**}Represents combined data for melanoma and nonmelanoma skin cancer.

Life Impact




^{*}Provides the total number of deaths and average age at death from skin infections compared with other skin diseases with highest mortality.



^{*}Estimate/projected number of life years lost due to non-cancerous skin growths compared to top skin diseases leading to early death; Projected based on prototypical lifespan of 75 years.

Life Impact



^{*}Time lost by patients and/or caregivers multiplied by average wages in 2013 (\$192/day); In millions of dollars compared with skin diseases leading to the most loss of productivity.

^{**}This category is clinically broad in nature and includes, among other diseases: benign neoplasms, melanocytic nevi (unspecified), pilar cysts, pilonidal cysts (with or without abscess), scars and fibrosis, etc.



Copyright © 2017 by American Academy of Dermatology. All rights reserved.

This information is intended for personal/noncommercial use and may not be reproduced in any form by any means (electronic, mechanical, or other) or held in any information storage and retrieval systems without written permission from the publisher.

Commercial use or distribution

For information on obtaining copies of this publication or to license the content for distribution, please visit www.aad.org/BSD for details and to complete an application.